E-Newsletter - July 2019
FUNDING SUPPORT FOR ALLIANCE MEMBERS AND INVESTIGATORS
Mark your calendars for the deadlines of these funding opportunities for Alliance member and investigators.
August 30 - Moertel Lecturer. This award was established in 1995 to honor the legacy of Charles G. Moertel, MD, as the founder of the North Central Cancer Treatment Group (NCCTG). The award acknowledges an investigator whose research within the NCI National Clinical Trials Network (NCTN) has resulted in a major impact on community cancer practice.
August 23 - Daniel J. Sargent, PhD Memorial Fellowship in Innovative Clinical Trial Design and Methods. This one-year, non-renewable fellowship award is in the amount of $15,000 for salary support. The award honors the contributions of Dr. Sargent to the field of clinical cancer research. The award is open to biostatistics faculty (exclusively) affiliated with the Alliance Statistics and Data Management Center (SDMC), preferably junior faculty, within seven (7) years post training (Associate Professor Rank or below). Proposals must be closely tied to the research agenda of the Alliance and Alliance SDMC. The work proposed should address study design and/or data analyses approaches that are directly relevant to current challenges faced with cancer clinical trials. In addition, the proposal should address achieving innovation in one or more of the following areas: cancer clinical trial design, prognostic and predictive biomarkers, endpoints, trial monitoring, and execution. The work should directly lead to a peer-reviewed publication, presentation or preliminary data for a grant proposal.
July 31 - Alliance Scholar Awards. These are two-year, non-renewable cancer research grants of $40,000 direct costs per year for two years. The awards are open exclusively for oncology junior faculty at Alliance institutions within five (5) years of training (rank below Associate Professor). Applicants must have completed training in an oncology clinical specialty (e.g., medical, surgical, radiation, gynecologic, etc.). Proposals must be nominated by an Alliance Scientific Committee Chair and be closely tied to the research agenda of the Alliance. Potential applicants must work with the relevant Alliance Scientific Committee Chair prior to submission of application to ensure endorsement of the relevant Alliance Scientific Committee and include a letter of support from the relevant Alliance Scientific Committee Chair with application materials. Projects supported by other non-institutional funds are not eligible.
July 31 - Richard L. Schilsky Cancer and Leukemia Group B Achievement Award. This award was established in 2010 to recognize the 15-year tenure of Dr. Schilsky as Group Chair of Cancer and Leukemia Group B (CALGB). The award acknowledges the significant contributions of an individual to cooperative group research. As an organization, it is vital for the Alliance to identify and honor the talented people responsible for its success. The award was made possible through generous donations from our members and industry supporters. All Alliance members are welcome to submit nominations for this award.
For other articles in this issue of the Alliance E-News newsletter, see below.
- Message From the Group Chair - Monica M. Bertagnolli, MD
-
PI Perspective: Alliance Health Outcomes Committee
Michelle Naughton, PhD and Amylou Dueck, PhD (Co-Chairs)
Jackie Lafky, MS (Program Manager) -
Changing the Guard: Director and PI, Alliance Central Protocol Operations Program
Gin F. Fleming, MD and Olwen Hahn, MD - Recent Alliance Protocol Activations
-
Spotlight on Alliance Trials
Alliance A091802 - Cutaneous squamous cell carcinoma
Alliance A041701 - Chronic myeloid leukemia
Alliance A031704 - Advanced renal cell cancer
Alliance A031702 - Rare genitourinary tumors - ICAREdata | Integrating Clinical Trials and Real World Endpoints
-
Adding Value to the Alliance Clinical Trial Process
Alliance Patient Advocate Committee -
Announcements
-- Alliance Joins with ASCO, CancerLinQ and The MITRE Corporation to Publish Initial Set of Common Cancer Data Standards and Specifications Comprising mCODE (VIDEO))
-- Recap: Alliance and Alliance Foundation Trials at 2019 ASCO
-- Renewed NCI Investigational Agent Accountability Record Forms (DARFs)
-- Call for Nominations + Applications: 2019/2020 Alliance Awards + Honors
-- Alliance Appoints New Committee Chairs -
Alliance in the News
-- GNS Healthcare Chosen to Present Discovery of New Clinical Predictors of Overall Survival in Metastatic Colorectal Cancer at ESMO 2019 in Collaboration with the Alliance for Clinical Trials in Oncology
-- mCODE Improves EHR Data Standardization for Cancer Research
-- First Patient Dosed in Phase III Study of E-Selectin Antagonist Uproleselan in AML (Alliance A041701)--ASCO 2019: CALGB 90601 (Alliance): Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Metastatic Urothelial Carcinoma
--'Magic Mouthwash' Little Help for Radiation-Induced Mucositis (Alliance A221304)
-- Magic mouthwash effective treatment for mouth sore pain caused by radiation therapy (Alliance A221304)
-- Mouthwashes Show Promise in Reducing Chemo-Related Oral Mucositis Pain (Alliance A221304)
-- Giving Drugs before Surgery Lowers the Risk of Prostate Cancer Returning (CALGB 90203)
-- Study: Identifying colorectal cancer subtypes could improve treatment (CALGB/SWOG 80405)
-- The Fight to Save the Bladder Turns to Genomics (Alliance A031701)